November 15
- November 17
Along with a series of studies we plan to present related to our experiences with hybrid LC-MS/MS technology, KCAS will also be presenting on a study where we analyzed a compound that involved looking at urea in plasma and lung fluid (urea, of course, being a biomarker). Urea is endogenous…
Blogs
Dr. Sohrab Habibi Goudarzi – Senior Director of Pharma Discovery and R&D Services, Bryan Parmentier – Senior Principal Scientist of Pharma Method Development, and Yu-Hui (Ann) Fu -Principal Scientist of Pharma Regulatory, along with other scientists at KCAS Bioanalytical & Biomarker Services, coauthored with scientists at Gilead Sciences, Inc. in…
Blogs
Although bioanalysis is KCAS’ principal area of expertise, we are always considering how we can build around those capabilities to ensure that we can provide optimal service for our clients. Our current breadth of service enables us to provide a comprehensive approach during non-GLP pre-clinical studies where it is feasible…
Blogs
Pharmacodynamics (PD) is defined as the study of the biochemical and physiological effects of drugs and the mechanisms of their actions. Where pharmacokinetics looks at how the organism processes the drug, pharmacodynamics studies…
Blogs
To read part one of this 2-part series, click here. With increasing focus on large molecule therapeutics and interest in large molecule biomarkers it’s essential to have LC/MS available as a complimentary technology to ligand…
Blogs
I have been studying Biological Markers (biomarkers) for over 25 years, but last 5 years they have exploded and become a key bioanalytical component to a drug’s success. Biomarkers are used to support drug…
Blogs
The workflow for bioanalytical LC-MS/MS requires isolation of analytes of interest from biological samples prior to analysis. This usually involves an extraction procedure ahead of injection into the LC-MS/MS system where the target compounds…
Blogs
A recent trend in the pipelines of pharmaceutical companies & biotechs has been a shift to large molecule therapeutics. This presents a challenge for bioanalysis by LC/MS because the molecular weights of the target…
webinars
Join us Tuesday November 10, 2020 at 11am EST| 8am PST| 4pm CET| 5pm CET Bioanalytical liquid chromatography–mass spectrometry (LC–MS) for small molecules is often referred to as a routine technology. That perception may be true for many drugs, but as pharmaceutical companies move into new areas, more projects may…
Blogs
Pharmacokinetic modeling during the drug development process is essential for determining whether an administered drug substance has the necessary characteristics to meet its intended medical use. Typically for small molecules bioanalysis, this is…